Welcome to our dedicated page for Neurogene news (Ticker: NGNE), a resource for investors and traders seeking the latest updates and insights on Neurogene stock.
Neurogene, Inc. (NGNE) is a clinical-stage biotechnology company focused on leveraging gene therapy to treat severe neurological diseases. With headquarters in Seattle, Washington, Neurogene's mission is to transform the lives of patients with complex neurological conditions through innovative genetic solutions. The company utilizes its proprietary EXACT gene regulation technology, which offers precise control over gene expression, enhancing the efficacy and safety of its treatments.
Neurogene's lead product candidate, NL-201, is designed to mimic the therapeutic benefits of cytokines interleukin (IL)-2 and IL-15. This de novo protein aims to treat various types of cancer, including renal cell carcinoma and melanoma. The company is dedicated to developing immunotherapies for cancer, inflammation, and autoimmunity disorders using advanced protein design technology.
Founded in 2003 and initially named Aquinox Pharmaceuticals, Inc., the company rebranded to Neoleukin Therapeutics, Inc. in August 2019, before evolving into the specialized entity it is today, Neurogene, Inc. The company has established significant partnerships and collaborations within the biotech industry, aiming to leverage these relationships to accelerate the development and commercialization of their gene therapy solutions.
Neurogene's financial health is bolstered by a robust pipeline of transformative therapies and a dedicated team of experts. The company continues to innovate and expand its research and development efforts, aiming to bring life-changing therapies to patients who currently have limited treatment options.
For the latest updates on Neurogene, Inc. (NGNE), including financial performance, new research, and other significant developments, visit the News section on StockTitan.
Neurogene (NASDAQ: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, announced participation in several upcoming conferences.
At the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, management will present a corporate overview and meet with investors.
On June 18-19, 2024, at the IRSF Rett Syndrome Scientific Meeting, interim safety data from the NGN-401 gene therapy trial for Rett syndrome will be presented by management and Dr. Bernhard Suter.
Additionally, Neurogene will participate in a fireside chat at the TD Cowen Genetic Medicines & RNA Summit on June 21, 2024. Live webcasts of these events will be available on Neurogene’s Investor Relations webpage.
Neurogene (NASDAQ: NGNE) announced that its NGN-401 gene therapy for Rett syndrome has been chosen by the FDA for the START Pilot Program, aimed at accelerating the development of rare disease therapies. NGN-401 is one of only three programs selected by the CBER division, due to its potential clinical benefits and readiness for clinical development.
This selection allows Neurogene enhanced communication with the FDA to resolve product-specific development issues promptly. Currently, NGN-401 is being evaluated in a Phase 1/2 clinical trial, focusing on safety, tolerability, and preliminary efficacy in female pediatric patients. Interim efficacy data is expected in Q4 2024.
Neurogene recently reported favorable safety data from the first three patients dosed. The START Program aims to provide frequent FDA advice to facilitate the program's development and generate high-quality data for potential future marketing applications.
Neurogene Inc. (Nasdaq: NGNE) reported its first quarter 2024 financial results and highlighted recent corporate updates, focusing on the NGN-401 gene therapy trial for Rett syndrome. The company presented favorable safety data at the ASGCT Annual Meeting, received Australian HREC approval for the trial, and remains on track to provide interim efficacy data in Q4:24. Neurogene maintains a strong balance sheet with cash runway into 2H:26.
Neurogene Inc. presented favorable safety data from the Phase 1/2 trial of NGN-401 Gene Therapy for Rett Syndrome at the ASGCT Annual Meeting. The therapy was well-tolerated by the first three patients dosed, showing no signs of overexpression toxicity. The company remains on track to provide interim efficacy data in the fourth quarter of 2024.
FAQ
What is the current stock price of Neurogene (NGNE)?
What is the market cap of Neurogene (NGNE)?
What does Neurogene, Inc. do?
What is Neurogene's lead product candidate?
Where is Neurogene, Inc. headquartered?
What technology does Neurogene use for its treatments?
When was Neurogene, Inc. founded?
What was the former name of Neurogene, Inc.?
What types of diseases does Neurogene aim to treat?
What is the EXACT gene regulation technology?
Does Neurogene have any partnerships?
How can I stay updated about Neurogene, Inc.?
